The patient-specific T-PLL cancer cell samples of the first cohort were treated with eight drugs (bendamustine [alkylating agent], cladribine [ribonucleotide reductase inhibitor with additional epigenetic mode of action], dinaciclib [CDK inhibitor], ibrutinib [BTK/ITK inhibitor], idasanutlin [MDM2 inhibitor], romidepsin [HDAC2 inhibitor], ruxolitinib [JAK inhibitor], venetoclax [BCL2 inhibitor]) using seven different doses. Here, BTK is linked to cancer.